Research & Trials
Clinical trials in both imaging and therapy is an important focus of the St Vincent’s Theranostics department. We published the world first prospective trial demonstrating the superiority of GaPSMA-11 PET CT in men with prostate cancer in 2015, with multiple publications since. Similarly we have undertaken multiple prospective trials in theranostics therapies in the last few years. We also published the first prospective trial that combined Lu PSMA with a radiation sensitiser in 2020.
The department works closely with the oncology unit at the Kinghorn Cancer Centre, the prostate cancer research centre, the Garvan institute of medical research, St Vincent’s Clinic and St Vincent’s Private Hospital to achieve high quality, meaningful research and optimal patient journeys.
We are now working with multiple biotech companies to provide avenues to fast-track new theranostics discoveries into the clinic with phase 1 clinical trials. It is a truly exciting time in Theranostics – so watch this space!!
Multiple trials are currently open and enrolling in the department. Please check the list below and contact our staff if you have any queries on 83821830
Imaging trials in accrual or due to start 2021
|
Trial Name
|
Trial type
|
Agent
|
Cancer Type
|
Status
|
PI
|
|
PRIMARY trial
|
Prospective
|
Ga PSMA -11
MRI
|
Prostate (diagnosis)
|
Open Jan 2021
|
Prof Emmett
|
|
PRIMARY 2 trial
|
Prospective randomised
|
Ga PSMA -11
MRI
|
Prostate (diagnosis)
|
Opening 2021
|
Prof Emmett
|
|
Detect trial
|
Prospective
|
Tc PSMA 11
|
Prostate (pre-RP)
|
Open Jan 2021
|
Prof Phil Stricker
|
|
BOBCAT trial
|
|
Cu64 Bombesin
|
Breast (ER/PR+)
|
Open Jan 2021
|
Prof Emmett
Prof Lim
|
|
BOBCAT trial
|
|
Cu 64 Bombesin
|
Prostate (PSMA negative)
|
Open 2021
|
Prof Emmett
|
|
CAA
|
|
|
Brain tumours
|
|
Prof Emmett
Novartis trial
|
|
PIAS trial
|
Prospective
|
Ga PSMA 11
|
Prostate active surveillance study
|
Open Q1 2021
|
Dr James Thompson
|
Therapy trials in accrual or due to start 2021
|
Trial Name
|
Cancer Type
|
Status
|
Principal investigator
|
|
ENZA-p trial: Ph2 enzalutamide vs enzalutamide + LuPSMA 617
|
Metastatic castrate resistant prostate cancer
|
Open and accruing Jan 2021
|
Prof Emmett
ANZUP trials
|
|
Upfront PSMA Ph2
Docetaxel vs Docetaxel + LuPSMA 617
|
Newly diagnosed metastatic prostate cancer
|
Open and accruing Jan 2021
|
Prof Hofman
PROStic
|
|
LuPARP: ph1
Lu PSMA +olaparib
|
Metastatic castrate resistant prostate cancer
|
Closed but ongoing Jan 2021
|
Dr Shahneen Sandhu
PMCC
|
|
PRINCE: Ph
Lu PSMA + immuno
|
Metastatic castrate resistant prostate cancer
|
Closed but ongoing Jan 2021
|
Dr Shahneen Sandhu
PMCC
|
Our Funders
The department has been the recipient of multiple grant funds for these important investigator initiated trials in the last few years. These funders include:
Movember / Prostate cancer research alliance: ($4,000,000.00) awarded for the ENZA-p trial – now open and accruing across Australia and run by ANZUP and then CTC NHMRC trial groups.
Cancer Institute NSW – $3,750,000 funding support for PRIMARY, LuPIN, and multiple other trials.
St Vincent’s Clinic Foundation - $400,000.00 for ENZAp and $40,000.00 for PRIMARY trial
St Vincent’s Curran Foundation - $100,000.00 for the PRIMARY trial.
The research papers generated from research performed within the Theranostic & Nuclear Medicine service are outlined below:
Ga PSMA vs Choline (PDF 476KB)
← Back To Main Page